Kura Oncology (NASDAQ:KURA) reported fourth-quarter and full-year 2025 financial results on Thursday, marked by the inaugural commercial sales of its newly approved AML treatment, KOMZIFTI.
The San Diego-based biopharmaceutical company posted a net loss of $81 million, or 92 cents per share, wider than the 72-cent loss per share projected by analysts surveyed by Zacks Investment Research.
The increased deficit reflects a surge in research and development and selling costs associated with the global Phase 3 KOMET-017 trial and the U.S. commercial rollout.
Quarterly revenue totaled $17.3 million, missing the $29.8 million consensus estimate.
This figure included $2.1 million in net product sales from KOMZIFTI's first five weeks on the market following its November approval.
For the full year, Kura reported a net loss of $278.7 million, or $3.18 per share, on revenue of $67.5 million.
Despite the earnings miss, the company ended the year with a robust cash position of $667.2 million.
Management indicated that current reserves, supplemented by $180 million in anticipated collaboration milestones from Kyowa Kirin, provide a capital runway into 2028.